Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches
Pharmaceutical Research · 2026
DOI: 10.1007/s11095-026-04151-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Petra Booij und 15 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Stevenage, UK. Hauptthemen laut MEDLINE: Drug Contamination. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Achieving the Analytical Evaluation Threshold (AET) for leachables is critical in quantification for patient safety evaluation but presents challenges for drug products with large dosing volumes or complex matrices. This paper reviews these challenges, presents industry perspectives, and proposes scientifically justified approaches to ensure patient safety where the AET is not analytically achievable. An industry-wide survey conducted by the Extractables and Leachables Safety Information Exchange (ELSIE) Consortium among 23 member companies identified common hurdles and alternative approaches used in leachables risk assessments. Findings were supplemented with case studies and a review of current analytical and regulatory strategies. The survey identified large dosing volumes (74% respondents) and matrix complexity (68% respondents) as the primary drivers for unachievable AETs. Matrix complexity was shown to significantly impact achievable limits of quantification (LOQs), with reported LOQs ranging from 100 ppb in complex matrices like protein-based or lipid-based formulations. Key analytical difficulties included identifying unknown leachables, background interference, and differentiating true leachables from analytical artifacts. When conventional screening methods cannot meet the AET, a robust, scientifically rationalized alternative approach is essential. Recommendations include implementing targeted leachable studies for enhanced sensitivity, using simulation studies to predict leachable profiles without matrix interference, and applying predictive modelling. For therapies addressing life-threatening conditions, a risk-benefit analysis leveraging the "less than lifetime" (LTL) concept may justify higher thresholds. Demonstrating rigorous method development efforts and providing scientific justification for the chosen strategy is crucial for regulatory alignment and ensuring patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Stevenage, UK.
- Bayer, Turku, Finland.
- EVER Valinject GmbH, Unterach, Austria.
- Maven E&L Ltd Consulting, Stevenage, UK.
- American Regent, New Albany, OH, USA.
- Pfizer Inc., Chesterfield, MO, USA.
Zitieren
APA
Booij, P., Nurmi, T., Pour, G., Creasey, J., Zhang, T., Hash, J., Amin, A., Duong, C., Chen, J., Zdravkovic, S. A., Helfrich, M., Verdonck, T., Müller, J., Sobańtka, A., McKenzie, C., & Bielinski, M. K. (2026). Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04151-y
Vancouver
Booij P, Nurmi T, Pour G, Creasey J, Zhang T, Hash J, et al. Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04151-y
BibTeX
@article{Booij2026,
author = {Booij, Petra and Nurmi, Tarja and Pour, Georg and Creasey, Jason and Zhang, Ting and Hash, Julie and Amin, Aeshna and Duong, Cindy and Chen, JoAnn and Zdravkovic, Steven A and Helfrich, Michael and Verdonck, Tim and Müller, Janine and Sobańtka, Alicja and McKenzie, Craig and Bielinski, Mary Kate},
title = {Low Analytical Evaluation Threshold in Leachables Screening: Challenges, Potential Solutions and Alternative Approaches},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04151-y}
}
EUVIMED